Deyaa Adib, MD



  • Clinical oncology expert with 20 years of extensive pharmaceutical experience, strong analytical capabilities in multidisciplinary areas of oncology research and development, and deep expertise in pharma and biotech: academic medicine and research (from clinic to bedside), pharmaceutical drug development (from preclinical to post-marketing), and medical/regulatory oversight review (from IND to NDA).

CMO; Development / Management / Oversight / Execution of Phases 1-4 Clinical Trials; Medical Regulatory Oversight and Review; Regulatory Submissions (NDAs, MAAs); Due Diligence; Business Development; Program Budget Oversight; Vendor Selection and Management; Biotech Startups; Clinical and Business Strategy / Planning; KOL Relations / Oversight; Advisory Boards; Medical Affairs; and Medical Lead – Mergers and Acquisitions.
Therapeutic Areas: Targeted therapies in oncology, solid tumor and hematologic malignancies (colorectal, ovarian, breast, lung, renal, prostate, head and neck, melanoma, leukemia/lymphoma). MD – Cairo University School of Medicine, Cairo, Egypt; Residency-Internal Medicine and Medical Oncology training – Anglo American Hospital Association, Gezira, Cairo, Egypt; United States Medical Licensing Examination / Educational Commission for Foreign Medical Graduates Certification (1995); Tufts University School of Medicine Certification – Clinical Pharmacology, Drug Development and Regulation (1999).
Biotech Startups
Focus on targeted therapies and I-O Programs; served as medical evaluation/due diligence lead, JDC/JSC membership (preclinical to registration-enabling trials developing CDP with trial designs for small molecule TKIs and checkpoint inhibitors / CAR-T cell therapies with licensing partners). Targets: KIT D842V, D816V, FLT3, VEGF, PD1, LAG3, TIM3, CD73 and CD19 in GIST, SM, AML, NSCLC, melanoma, SCCHN and B-cell malignancies.
Business Development
Strategy presentations to boards of directors; prepped slides and handled Q&A for investors and advocacy groups.
As medical lead/TA Head, conducted over 40 due diligence clinical evaluations to build Oncology Portfolios, as well as partnership evaluations, leading to securing alliances/mergers/acquisitions with Medivation ($1B), Merrimack ($900m ), Ambit ($200m), Aveo ($250m); performed M&A leading to acquiring Oncaspar ($900m), Baxalta acquisition – Shire ($32B), Ariad acquisition – Takeda ($5.1B), OSI acquisition – Astellas ($4.1B).
Medical Affairs
Established relations/led KOL meetings (IDMC, Steering Committees, advisory boards); contributed clinical/safety sections for IND/NDA/MAA/NDS/FDA briefing documents; led medical affairs team and supported IST proposal reviews, publication planning, MSL trainings, and advisory boards; and performed pharmacovigilance for conventional cytotoxic agents, small molecules, biologics, liposomal, and nanoparticles:

  • Led NDA, MAA, and PMDA submission of Nal-IRI (liposomal irinotecan), provided responses to HA requests during review, and presented at the EMA and PMDA pivotal trial pre-submission meetings, resulting in successful US and EU approval.
  • Led clinical and safety sections of enzalutamide in CRPC (erlotinib) in NSCLC NDA and provided responses to FDA queries during review, leading to expedited review and approval.
  • Contributed to NDA of taxotere in HRPC, establishing first SOC with successful expedited review / approval.
  • Led the IND and CDP for three checkpoint inhibitors (PD1, LAG3, TIM3) in solid tumors, and pre-IND submission for CD19 CAR-T in B-cell malignancies.
  • As clinical lead, presented at face-to-face meetings with FDA, EMA, PMDA, and Heath Canada.
  • Created clinical strategy and successfully executed Phase 1 to Phase 4 clinical trials in oncology; led multiple Phase 3 global studies in oncology.
  • Participated in regulatory meeting development, including Type C and A and pre-IND.

Acting CMO, Rain Therapeutics
Clinical Development Head and Acting CMO Hematology/Oncology, MariCel Clinical Consulting
Global Medical Leader – Hematology, ARIAD (acquired by Takeda)
Global Head – Solid Tumors, Baxalta Oncology (acquired by Shire)
Senior Medical Director – Oncology, Astellas Pharma
Associate Director – Global Safety Officer, Oncology, Sanofi-Aventis, Global Pharmacovigilance and Epidemiology

Join Today

Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Cras ultricies ligula sed dictum porta. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Curabitur arcu erat, accumsan id imperdiet et